Search

Displaying results 1251 - 1260 of 10000 in total
  1. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

  2. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

    Mixtures: VAPRINEXT-D, Marcaine ESynonyms: DL-Bupivacaine, 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
  3. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … Growth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood

  4. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

    Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamine
  5. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower … Osteosarcoma is the most common primary malignant bone tumor that usually arises in the metaphyses of long bone in children and adolescents [A31744].

  6. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.

    Products: innohep 8.000 IE/0,4 ml Injektionslösung in einer Fertigspritze, innohep 10.000 IE/0,5 ml Injektionslösung in einer Fertigspritze
  7. Drug

    Methotrimeprazine

    go.drugbank.com/drugs/DB01403
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

    Synonyms: (-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amineCategories: Dopamine D2 Receptor Antagonists
  8. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    In addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516]. … The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 [T178].

  9. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

  10. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution

    Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide